OrsoBio announces positive topline Phase 1b/2a clinical data for its oral mitochondrial protonophore TLC-6740 in combination ...
MedPage Today on MSN
One GLP-1 Drug May Be Better Than Rivals for Glaucoma Risk
Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...
Using tirzepatide is linked to lower risks of developing primary open-angle glaucoma and elevated eye pressure in patients ...
The best weight loss medication for men includes semaglutide (Ozempic , Wegovy ), tirzepatide (Mounjaro , Zepbound ), and ...
Trials have shown that semaglutide can reduce major cardiovascular events, but the extent of tirzepatide’s heart protection has been less clear. A team at Mass General Brigham set out to compare both ...
The move broadens treatment choices for pediatric patients aged 10 years and older whose diabetes remains uncontrolled with ...
The SURMOUNT-1 trial evaluated Tirzepatide a dual GIP/GLP1 agonist, in individuals with overweight (BMI more than or equal to ...
In patients with coronary artery disease (CAD) and obesity, tirzepatide was associated with lower mortality and reduced ...
3don MSNOpinion
Lawmakers must expand coverage for obesity treatment
Congress has the power to make obesity treatment and weight management accessible to the communities that need it.
10hon MSN
Is Eli Lilly a buy before 2026?
Eli Lilly’s next-generation obesity treatment may prove highly effective for patients who have high BMI or suffer from ...
7hon MSN
The highly anticipated 'triple agonist' weight loss med is almost here—what doctors say about it
As for this specific alternative, the weight loss results are “remarkable” so far, says Gitanjali Srivastava, MD, co-director ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results